Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 12, 2008, Pages 1449-1455

  Rodrigues, Camilla ^a   Jani, J ^b   Shenai, S ^a   Thakkar, P ^a   Siddiqi, S ^c   Mehta, A ^a  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

^b Becton Dickinson Diagnostic Systems   (India)

^c BD Technologies   (United States)

Author keywords

Drug susceptibility testing; India; MGIT 960

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; ETHIONAMIDE; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; LABORATORY APPARATUS, EQUIPMENT AND SUPPLIES; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS;

EID: 58049201704     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Aziz M A, Wright A, Laszlo A, et al. Epidemiology of anti-tuberculosis drug resistance (the Global Project on Anti-Tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006; 368: 2142-2154.
2. Balabanova, Y, Ruddy M, Hubb J, et al. Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy. Eur J Clin Microbiol Infect Dis 2005; 24: 136-139.
3. Toungoussova O S, Mariandyshev A O, Bijune G, Caugant D A, Sandven P. Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel Oblast, Russia, to second-line anti-tuberculosis drugs. Eur J Microbiol Infect Dis 2005; 24: 202-206.
4. World Health Organization. Anti-tuberculosis drug resistance in the World. Report no. 3. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. WHO/HTM/TB/2004.343. Geneva, Switzerland: WHO, 2004.
5. Gandhi N R, Moll A, Sturm A W, et al. Extensive drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
6. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR 2006; 55: 301-305.
7. Pfyffer G E, Bonato D A, Ebrahimzadeh A, et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric Bactec 460 technique and the proportion method with solid media. J Clin Microbiol 1999; 37: 3179-3186.
8. Tenover F C, Crawford J K, Huebner R E, Geiter L H, Horsburgh R Jr, Good R C. The resurgence of tuberculosis: is your laboratory ready? J Clin Microbiol 1993; 31: 767-770.
9. Adjers-Koskela K, Katila M L. Susceptibility testing with the Manual Mycobacteria Growth Indicator Tube (MGIT) and the MGIT 960 System provides rapid and reliable verification of multidrug-resistant tuberculosis. J Clin Microbiol 2003; 41: 1235-1239.
10. Bemer P, Palicova F, Rüsch-Gerdes S, Drugeon H B, Pfyffer G E. Multicenter evaluation of fully automated Bactec Mycobacteria Growth Indicator Tube 960 System for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2002; 40: 150-154.
11. Goloubeva V, Lecocq M, Lassowsky P, Matthys F, Portaels F, Bastian I. Evaluation of Mycobacteria Growth Indicator Tube for direct and indirect drug susceptibility testing of Mycobacterium tuberculosis from respiratory specimens in a Siberian prison hospital. J Clin Microbiol 2001; 39: 1501-1505.
12. Huang T S, Tu H Z, Lee S S, Huang W K, Liu Y C. Antimicrobial susceptibility testing of Mycobacterium tuberculosis to first-line drugs: comparisons of the MGIT 960 and Bactec 460 Systems. Ann Clin Lab Sci 2002; 32: 142-147.
13. Kantos F, Maniati M, Castopoulos C, et al. Evaluation of the fully automated Bactec MGIT 960 system fot the susceptibility testing of Mycobacterium tuberculosis to first-line drugs: a multicenter study. J Microbiol Methods 2004; 56: 292-294.
14. Palomino J C, Traore H, Fissette K, Portaels F. Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 1999; 3: 344-348.
15. Rüsch-Gerdes S, Domehl C, Nardi G, Gismondo M R, Welscher H M, Pfyffer G E. Multicenter evaluation of the mycobacterial growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs. J Clin Microbiol 1999; 37: 45-48.
16. Scarparo C, Ricordi P, Ruggiero G, Piccoli P. Evaluation of the fully automated Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampicin and ethambutol and comparison with the radiometric Bactec 460 method. J Clin Microbiol 2004; 42: 1109-1114.
17. Kruuner A, Yates M D, Drobniewski F A. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of M. tuberculosis. J Clin Microbiol 2006; 44: 811-818.
18. Rüsch-Gerdes S, Pfyffer G E, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of drug susceptibility testing of Mycobacterium tuberculosis against classical second-line drugs and newer antimicrobials by Bactec MGIT 960 Technique. J Clin Microbiol 2006; 44.3: 688-692.
19. Siddiqi S H. Bactec 460 TB System. Product and procedure manual, revision D. Sparks, MD, USA: Becton Dickinson Diagnostic System, 1995.
20. Siddiqi S H, Rüsch-Gerdes S. MGIT procedure manual. Geneva, Switzerland: Foundation for Innovative New Diagnostics, 2006.
21. Bastian I, Rigouts L, Palomino J C, Portaels F. Kanamycin susceptibility testing of Mycobacterium tuberculosis using Mycobacterium Growth Indicator Tube and a colorimetric method. Antimicrob Agents Chemother 2001; 45: 1934-1936.
22. Huang T S, Lee S J, Tu H Z, et al. Use of MGIT 960 for rapid quantitative measurement of the susceptibility of Mycobacterium tuberculosis complex to ciprofloxacin and ethionamide. Antimicrob Chemother 2004; 53: 600-603.
23. Pfyffer G E, Bonato D A, Ebrahimzadeh A, et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric Bactec 460 technique and the proportion method with solid media. J Clin Microbiol 1999; 37: 3179-3186.
24. Tortoli E, Dionisio D, Fabbri C. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis including resistant and multidrug-resistant strains. J Chemother 2004; 16: 334-336.
25. Almeida D, Rodrigues C, Udwadia Z F, Lalvani A, Gothi G D, Mehta P. Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for prevention. Clin Infect Dis 2003; 36: 152-154.
26. Shinnick T M, Iademarco M F, Ridderhof J C. National plan for reliable tuberculosis laboratory services using a systems approach. Recommendations from CDC and the Association of Public Health Laboratories Task Force on Tuberculosis Laboratory Services. MMWR Recomm Rep 2005; 54: 1-12.